Biosimilars: To switch or not to switch – that is the question
Guardado en:
Autor principal: | Zoltán Szekanecz |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Termedia Publishing House
2020
|
Materias: | |
Acceso en línea: | https://doaj.org/article/aac0ef44f17340408383238d09bca268 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Safety of switching between rituximab biosimilars in onco-hematology
por: Silvana A. M. Urru, et al.
Publicado: (2021) -
Switching and Discontinuation Patterns Among Patients Stable on Originator Infliximab Who Switched to an Infliximab Biosimilar or Remained on Originator Infliximab
por: Fitzgerald T, et al.
Publicado: (2021) -
Analysis of real-world treatment patterns in a matched rheumatology population that continued innovator infliximab therapy or switched to biosimilar infliximab
por: Yazici Y, et al.
Publicado: (2018) -
Long-term safety and efficacy of biosimilar infliximab among patients with inflammatory arthritis switched from reference product
por: Abdalla A, et al.
Publicado: (2017) -
Multi-Hop Question Generation Using Hierarchical Encoding-Decoding and Context Switch Mechanism
por: Tianbo Ji, et al.
Publicado: (2021)